Mark Hahn - May 3, 2022 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Chief Financial Officer
Signature
/s/ Claire Poll, Attorney-in-fact for Mark Hahn
Stock symbol
VRNA
Transactions as of
May 3, 2022
Transactions value $
-$6,201
Form type
4
Date filed
5/5/2022, 07:18 PM
Previous filing
May 3, 2022
Next filing
Aug 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Sale -$6.2K -12.5K -0.08% $0.50* 15.4M May 3, 2022 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units.
F3 The price reported represents the sale price of the ADSs divided by eight (8).
F4 Consists of (i) 8,191,744 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,023,968 ADSs); and (ii) 7,189,776 Ordinary Shares underlying 898,722 ADSs.